1. Market Research
  2. > Healthcare
  3. > Blood Supply, Tissue Banking and Transplantation Market Trends
  4. > Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile

Summary

Cerus Corporation (Cerus) is a biomedical products manufacturing company which develops and commercializes Intercept Blood System for blood safety. The company has rights of Intercept for three blood components, namely, platelets, red blood cells and plasma. The system is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells (WBC) included in donated blood components intended for transfusion. It markets its product in the US, Europe, Russia, the Middle East and selected countries of other regions of the world for the treatment of both platelets and plasma for transfusions and it is also being developed for the treatment of red blood cells. Cerus is headquartered in Concord, California, the US.

Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 6
Cerus Corporation, Medical Equipment Deals By Type, 2010 to YTD 2016 7
Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016 8
Cerus Corporation, Medical Equipment, Deals By Market, 2010 to YTD 2016 9
Cerus Corporation, Medical Equipment, Deals Summary, 2010 to YTD 2016 10
Cerus Corporation, Medical Equipment, Deal Details 11
Partnerships 11
Cerus Terminates Licensing Agreement With BioOne 11
Cerus Enters into Agreement with Haemonetics 12
Cerus Enters into Agreement with Kawasumi Labs to Develop Intercept Platelets Kits in Japan 13
Cerus Enters into Co-Marketing Agreement with Biomedica Foscama 14
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma 15
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma 16
Cerus Enters Into Distribution Agreement With Ilex Biotech 17
Cerus Enters Into Agreement With CSL 18
Equity Offering 19
Cerus Plans to Raise USD70 Million in Public Offering of Shares 19
Cerus Prices Public Offering of Shares for USD70 Million 20
Cerus Completes Public Offering Of Shares For US$40.3 Million 22
Cerus Completes Underwritten Public Offering Of US$21 Million 24
Cerus Corporation - Key Competitors 26
Key Employees 27
Locations And Subsidiaries 28
Head Office 28
Other Locations and Subsidiaries 28
Recent Developments 29
Financial Announcements 29
May 03, 2016: Cerus Corporation Reports First Quarter 2016 Results 29
Mar 08, 2016: Cerus Reports Fourth Quarter and Year End 2015 Results 31
Nov 05, 2015: Cerus Reports Third Quarter 2015 Results 33
Aug 06, 2015: Cerus Reports Second Quarter 2015 Results 35
May 05, 2015: Cerus Reports First Quarter 2015 Results 37
Feb 26, 2015: Cerus Reports Fourth Quarter and Year-End 2014 Results 39
Corporate Communications 41
Jan 11, 2016: Cerus Appoints New Leadership for Europe, Middle East and Africa Region 41
Jun 08, 2015: Richard J. Benjamin, MD PhD Appointed as Cerus Corporation's New Chief Medical Officer 42
Product News 43
Mar 16, 2016: Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma 43
Mar 15, 2016: Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA's Revised Guidance Document on Bacterial Safety Standards for Platelets 44
Mar 09, 2016: Blood Centers of America Selects Cerus as its Supply Partner for Pathogen Reduction Technology 45
Feb 09, 2016: Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma 46
Jan 14, 2016: AABB Authorizes Use of the INTERCEPT Blood System for Platelets to Reduce the Risk of Transfusion-Associated Graft Versus Host Disease 47
Jan 05, 2016: Cerus Announces Agreement with Blood Systems for the Use of INTERCEPT Platelets and Plasma 48
Dec 10, 2015: Cerus Announces Agreement with the National Transfusiology Center of Mongolia for the Use of INTERCEPT Platelets and Plasma 49
Dec 07, 2015: Cerus and Shepeard Community Blood Center Enter into Agreement for the Use of INTERCEPT Platelets and Plasma 50
Nov 02, 2015: Cerus Announces CMS Issuance of Permanent P-Codes for Outpatient Hospital Billing of Pathogen-Reduced Platelets and Plasma 51
Apr 27, 2015: Cerus To Present At AABB Symposium On Pathogen-Reduced Components 52
Mar 16, 2015: First Patient Enrolled In Cerus' True Study With The American Red Cross To Address Chikungunya And Dengue Blood Safety Risks With Pathogen Reduced Platelets 53
Feb 27, 2015: Cerus Signs INTERCEPT Platelet Agreement With Sweden's Largest Blood Product Supplier 54
Jan 28, 2015: Ash Stevens to Manufacture Amotosalen Active Pharmaceutical Ingredient for Cerus' INTERCEPT Blood System 55
Jan 05, 2015: Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint 56
Product Approvals 57
Mar 16, 2016: Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma 57
Clinical Trials 58
Mar 16, 2015: First Patient Enrolled In Cerus' True Study With The American Red Cross To Address Chikungunya And Dengue Blood Safety Risks With Pathogen Reduced Platelets 58
Jan 05, 2015: Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint 59
Other Significant Developments 60
Jul 11, 2016: Cerus Provides an Update on Adoption by Blood Centers of America Members for the INTERCEPT Blood System for Platelets and Plasma 60
Oct 21, 2015: Cerus Announces New Agreement With Fresenius Kabi for the Production of INTERCEPT Blood System Kits 62
Jul 13, 2015: Cerus and Bonfils Blood Center Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Cerus Corporation, Medical Equipment, Key Facts, 2015 1
Cerus Corporation, Medical Equipment, Deals Summary, 2010 to YTD 2016 1
Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 6
Cerus Corporation, Medical Equipment Deals By Type, 2010 to YTD 2016 7
Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016 8
Cerus Corporation, Deals By Market, 2010 to YTD 2016 9
Cerus Corporation, Medical Equipment, Deals Summary, 2010 to YTD 2016 10
Cerus Terminates Licensing Agreement With BioOne 11
Cerus Enters into Agreement with Haemonetics 12
Cerus Enters into Agreement with Kawasumi Labs to Develop Intercept Platelets Kits in Japan 13
Cerus Enters into Co-Marketing Agreement with Biomedica Foscama 14
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma 15
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma 16
Cerus Enters Into Distribution Agreement With Ilex Biotech 17
Cerus Enters Into Agreement With CSL 18
Cerus Plans to Raise USD70 Million in Public Offering of Shares 19
Cerus Prices Public Offering of Shares for USD70 Million 20
Cerus Completes Public Offering Of Shares For US$40.3 Million 22
Cerus Completes Underwritten Public Offering Of US$21 Million 24
Cerus Corporation, Key Competitors 26
Cerus Corporation, Key Employees 27
Cerus Corporation, Subsidiaries 28

List of Figures
Cerus Corporation, Medical Equipment, Deals by Type, 2010 to YTD 2016 1
Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 1
Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016 1
Cerus Corporation, Medical Equipment, Deals By Market, 2010 to YTD 2016 1
Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 6
Cerus Corporation, Medical Equipment, Deals by Type, 2010 to YTD 2016 7
Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016 8
Cerus Corporation, Medical Equipment, Deals by Market, 2010 to YTD 2016 9

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Haemonetics Corporation (HAE) - Product Pipeline Analysis, 2016 Update

Haemonetics Corporation (HAE) - Product Pipeline Analysis, 2016 Update

  • $ 750
  • Company report
  • July 2016
  • by Global Data

Summary Haemonetics Corporation (Haemonetics) is a healthcare company, which offers blood management technology and software solutions. The company’s portfolio consists of integrated devices, information ...

Terumo Corporation (4543) - Product Pipeline Analysis, 2016 Update

Terumo Corporation (4543) - Product Pipeline Analysis, 2016 Update

  • $ 750
  • Company report
  • May 2016
  • by Global Data

Summary Terumo Corporation (Terumo) is a medical technology company. It manufactures and sells a wide range of medical care products including hospital and medical products, equipment and pharmaceuticals. ...

Sanquin Blood Supply Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sanquin Blood Supply Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2016
  • by Global Data

Summary Sanquin Blood Supply Foundation (Saquin) is a nonprofit organization that supplies blood and promotes transfusion medicine. The foundation’s products and services include plasma products, blood ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.